Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 72
- Registration Number
- NCT00649194
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 1142
- Registration Number
- NCT00614536
Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.
Phase 3
Completed
- Conditions
- Gastroesophageal RefluxHeartburn
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 48
- Registration Number
- NCT00553449
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 236
- Registration Number
- NCT00539240
- Locations
- 🇺🇸
Southern Arizona VA Health Care System, Tucson, Tucson, Arizona, United States
Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients
Not Applicable
Completed
- Conditions
- LaryngitisGastroesophageal Reflux
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 200
- Registration Number
- NCT00517114
- Locations
- 🇨🇳
Queen Mary Hospital, Hong Kong, China
A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study
Not Applicable
- Conditions
- Chest Pain
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 200
- Registration Number
- NCT00517270
- Locations
- 🇨🇳
Queen Mary Hospital, Hong Kong, China
Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol
Terminated
- Conditions
- Gastroesophageal Reflux
- Interventions
- Other: Non-Pharmacologic Treatment
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Janssen-Cilag, S.A.
- Target Recruit Count
- 1049
- Registration Number
- NCT00511966
A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 1392
- Registration Number
- NCT00464308
A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole
Phase 1
Completed
- Conditions
- GERD
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 37
- Registration Number
- NCT00378287
CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00354757
- Locations
- 🇨🇳
National Taiwan Univeristy Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath